Erratum: Vol. 70, No. 12

Weekly / April 2, 2021 / 70(13);502

Print
Related Pages
View suggested citation
Table
Related Materials

In the report “Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine — United States, 2003–2018,” on page 417, Table 1 contained alignment errors. The corrected table is as follows:

Top

TABLE 1. Prevalence of human papillomavirus (HPV) infection among females aged 14–34 years, by age group and survey years — National Health and Nutrition Examination Survey, United States, 2003–2018*Return to your place in the text
Age group (yrs) and HPV types Prevaccine era 2003–2006 2007–2010 2011–2014 2015–2018 Comparison of 2015–2018 with 2003–2006
% (95% CI) PR (95% CI) aPR (95% CI)†
14–19 n = 1,363 n = 740 n = 797 n = 666 — —
4vHPV§ 11.5 (9.1–14.4) 5.0 (3.8–6.6) 3.3 (1.9–5.8) 1.1 (0.5–2.4) 0.10 (0.05–0.21) 0.12 (0.06–0.26)
Additional five types in 9vHPV** 8.4 (6.6–10.6) 6.1 (4.4–8.5) 5.3 (3.4–8.4) 2.3 (1.3–4.1) 0.28 (0.15–0.51) 0.35 (0.18–0.65)
Non-4vHPV†† 31.2 (27.9–34.8) 25.3 (21.4–29.5) 25.5 (21.3–30.2) 20.9 (16.9–25.6) 0.67 (0.53–0.84) 0.72 (0.57–0.92)
Non-9vHPV§§ 29.0 (26.0–32.2) 24.4 (20.8–28.4) 24.7 (20.6–29.4) 20.6 (16.6–25.3) 0.71 (0.57–0.90) 0.77 (0.61–0.98)
20–24 n = 432 n = 445 n = 442 n = 368 — —
4vHPV§ 18.5 (14.9–22.8) 19.9 (15.4–25.3) 7.2 (4.7–11.1) 3.3 (1.7–6.3) 0.18 (0.09–0.35) 0.19 (0.09–0.40)
Additional five types in 9vHPV** 16.5 (11.3–23.4) 13.8 (10.2–18.2) 13.2 (8.8–19.4) 10.2 (7.2–14.4) 0.62 (0.38–1.02) 0.62 (0.38–1.01)
Non-4vHPV†† 50.7 (43.4–58.0) 57.4 (51.3–63.3) 55.8 (49.9–61.6) 49.9 (42.3–57.5) 0.98 (0.80–1.21) 0.97 (0.80–1.18)
Non-9vHPV§§ 47.6 (40.7–54.6) 54.9 (48.9–60.8) 53.4 (47.8–58.8) 47.1 (39.7–54.7) 0.99 (0.80–1.22) 0.97 (0.79–1.18)
25–29 n = 403 n = 414 n = 395 n = 430 — —
4vHPV§ 11.8 (8.8–15.6) 13.1 (10.0–17.2) 8.8 (6.3–12.1) 9.1 (5.8–14.0) 0.77 (0.46–1.29) 0.85 (0.50–1.46)
Additional five types in 9vHPV** 10.8 (7.3–15.7) 13.1 (9.7–17.3) 13.9 (10.5–18.1) 11.6 (8.1–16.3) 1.07 (0.64–1.79) 0.99 (0.58–1.67)
Non-4vHPV†† 43.8 (38.9–48.9) 48.6 (43.7–53.6) 43.7 (37.7–49.9) 45.2 (39.2–51.4) 1.03 (0.87–1.23) 1.05 (0.86–1.27)
Non-9vHPV§§ 39.8 (34.8–45.0) 44.7 (40.0–49.4) 42.0 (36.2–48.0) 42.1 (36.6–47.9) 1.06 (0.88–1.27) 1.07 (0.88–1.31)
30–34 n = 389 n = 433 n = 433 n = 413 — —
4vHPV§ 9.5 (6.7–13.2) 8.9 (6.5–11.9) 7.1 (5.1–9.9) 6.2 (4.0–9.5) 0.65 (0.38–1.11) 0.67 (0.37–1.21)
Additional five types in 9vHPV** 9.8 (7.1–13.5) 6.8 (4.7–9.9) 6.9 (4.6–10.0) 6.9 (4.4–10.8) 0.70 (0.41–1.21) 0.68 (0.37–1.27)
Non-4vHPV†† 44.5 (39.1–50.1) 37.8 (31.6–44.5) 39.2 (33.6–45.0) 34.7 (29.1–40.8) 0.78 (0.63–0.96) 0.82 (0.67–1.00)
Non-9vHPV§§ 40.4 (35.0–46.0) 36.1 (30.3–42.3) 38.2 (32.7–44.0) 31.9 (26.6–37.6) 0.79 (0.64–0.98) 0.83 (0.67–1.03)

Abbreviations: aPR = adjusted prevalence ratio; CI = confidence interval; 4vHPV = quadrivalent HPV vaccine; 9vHPV = 9-valent HPV vaccine; PR = prevalence ratio.
* All analyses were weighted using the National Health and Nutrition Examination Survey examination sample weights.
† Adjustments for aPR: females aged 14–19 years, race/ethnicity and ever had sex; females aged 20–24, 25–29, and 30–34 years, race/ethnicity and number of lifetime sex partners (fewer than three or three or more).
§ HPV 6, 11, 16, or 18.
Relative standard error >30% and ≤50%, considered unstable.
** HPV 31, 33, 45, 52, or 58.
†† Thirty-three HPV types detected using linear array that are not HPV 6, 11, 16, or 18.
§§ Twenty-eight HPV types detected using linear array that are not HPV 6, 11, 16, 18, 31, 33, 45, 52, or 58.

Top


Suggested citation for this article: Erratum: Vol. 70, No. 12. MMWR Morb Mortal Wkly Rep 2021;70:502. DOI: http://dx.doi.org/10.15585/mmwr.mm7013a6.

MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.

Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

View Page In: PDF [56K]